On Sept. 14, 2021, Regeneron announced an agreement with the U.S. Department of Health and Human Services and the Department of Defense to purchase 1.4 million additional doses of REGEN-COV (casirivimab and imdevimab). The government continued to provide REGEN-COV at no cost to patients.

Under the new agreement, Regeneron will supply an additional 1.4 million 1,200 mg doses of REGEN-COV to the U.S. government by January 31, 2022, at a cost of $2,100 per dose. This new agreement follows two earlier agreements with the U.S. government announced in July 2020 and January 2021.

REGEN-COV is an investigational medicine authorized by the U.S. Food and Drug Administration (FDA) under an emergency use authorization to treat people who are at high risk of serious consequences from COVID-19 infection who are either already infected (non-hospitalized) or in certain post-exposure prophylaxis settings.